Analytical Data
-
Gene name
Cst7
- Application
-
Alternative Names
Cystatin-7 (Cystatin-like metastasis-associated protein) (CMAP) (Leukocystatin)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O89098
-
Expression Region
19-144aa
-
Molecular Weight
20.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CST7, or Cystatin F, is a member of the cystatin superfamily, which plays a crucial role in regulating protease activity and modulating immune responses. Its significance has emerged in various biological contexts, including inflammation, cancer, and autoimmune diseases. Research indicates that CST7 is involved in the regulation of macrophage activation and the modulation of T cell responses, thereby influencing the overall immune environment in pathological conditions. Additionally, alterations in CST7 expression have been linked to the progression of certain cancers, suggesting its potential as a biomarker for disease states or therapeutic targets. The recombinant protein form of CST7 has been developed for experimental studies to elucidate its functional properties and therapeutic potential further. Characterizing the structure and function of CST7 through recombinant technology allows researchers to explore its interactions with proteases and its impact on immune cell behavior in vitro and in vivo. As such, CST7 stands out as a promising subject for investigations aimed at understanding immune regulation mechanisms and developing novel therapeutic strategies for diseases characterized by immune dysregulation.
